Prevalence of HLA antibodies and its impact on graft function in a group of kidney transplant recipients:: A cross-sectional study

被引:9
作者
Morales-Buenrostro, L. E.
Buzo-Romero, J. M.
de Leo, C.
Lopez, M.
Ortiz-Arroyo, V. M.
Perez-Garrido, J.
Herrera-Garcia, C.
Granados, J.
Alberu, J.
机构
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Nephrol Mineral Metab, Mexico City 14000, DF, Mexico
[2] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Transplantat, Mexico City 14000, DF, Mexico
[3] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Immunol, Mexico City 14000, DF, Mexico
关键词
D O I
10.1016/j.transproceed.2006.02.035
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HLA alloantibodies (Abs) are associated with chronic rejection and poorer graft survival. The current study was designed to document the prevalence of HLA Abs in a group of kidney transplant recipients (KTR) and its impact on graft function. Patients and Methods. 283 KTR transplanted between January 1990 and December 2003 who had a functional graft were invited to participate. 198 KTR were enrolled. HLA class I and II Abs were measured by Luminex-One Lambda. Graft function was assessed by Delta Cr and GFR calculated by the Levey formula. Results. Median post-kidney transplant (post-KT) follow-up was 51.4 (4.3 to 176.3) months. Forty-four (22.2%) KTR were found to have class I and/or class II Abs. Eleven had both class I and II Abs, ten were positive only for class I, and 23 for class II. Overall, no significant difference was seen in renal function. The Delta Cr for Ab positive and Ab negative were -0.24 +/- 0.84 and -0.17 +/- 0.60 mg/dL (P=0.54), respectively. The GFR for Ab positive and Ab negative were 64.4 +/- 26 and 60.2 +/- 20 mL/min (P=0.25), respectively. No statistically significant difference was found between HLA Abs and number of HLA mismatches, gender, blood transfusions, pre-KT pregnancies, DGF, history of acute rejection, and chronic allograft nephropathy. Adjusting analysis by transplant year showed no significant difference. Conclusion. The prevalence of HLA antibodies was similar to previous reports. In this cross-sectional study, the presence of HLA antibodies was not related to a negative impact on renal function.
引用
收藏
页码:899 / 902
页数:4
相关论文
共 13 条
[1]   Complement C4d in graft capillaries - the missing link in the recognition of humoral alloreactivity [J].
Feucht, HE .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (06) :646-652
[2]   All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies [J].
Lee, PC ;
Terasaki, PI ;
Takemoto, SK ;
Lee, PH ;
Hung, CJ ;
Chen, YL ;
Tsai, A ;
Lei, HY .
TRANSPLANTATION, 2002, 74 (08) :1192-1194
[3]   Humoral rejection of human organ transplants [J].
Michaels, PJ ;
Fishbein, MC ;
Colvin, RB .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2003, 25 (02) :119-140
[4]   Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure [J].
Mizutani, K ;
Terasaki, P ;
Rosen, A ;
Esquenazi, V ;
Miller, J ;
Shih, RNJ ;
Pei, R ;
Ozawa, M ;
Lee, J .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (09) :2265-2272
[5]   Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants [J].
O'Rourke, RW ;
Osorio, RW ;
Freise, CE ;
Lou, CD ;
Garovoy, MR ;
Bacchetti, P ;
Ascher, NL ;
Melzer, JS ;
Roberts, JP ;
Stock, PG .
CLINICAL TRANSPLANTATION, 2000, 14 (02) :167-173
[6]   Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies [J].
Opelz, G .
LANCET, 2005, 365 (9470) :1570-1576
[7]   Medical progress - Strategies to improve long-term outcomes after renal transplantation [J].
Pascual, M ;
Theruvath, T ;
Kawai, T ;
Tolkoff-Rubin, N ;
Cosimi, AB .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) :580-590
[8]   Signal transduction via MHC class I molecules in endothelial and smooth muscle cells [J].
Reed, EF .
CRITICAL REVIEWS IN IMMUNOLOGY, 2003, 23 (1-2) :109-128
[9]  
Stegall MD, 2005, AM J TRANSPLANT, V5, P292
[10]   Predicting kidney graft failure by HLA antibodies: a prospective trial [J].
Terasaki, PI ;
Ozawa, M .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (03) :438-443